Evidence map›Paper›PMID 26071654›Full record

ArticleAtherosclerosis2015

Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans.

Nirav K Desai, Esther M Ooi, Paul D Mitchell, Jeremy Furtado, Frank M Sacks

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Nirav K DesaiDivision of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Esther M OoiSchool of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Paul D MitchellClinical Research Center, Boston Children's Hospital, Boston, MA, USA.
Jeremy FurtadoDepartment of Nutrition, Harvard School of Public Health and Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Frank M SacksDepartment of Nutrition, Harvard School of Public Health and Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: fsacks@hsph.harvard.edu.
Brigham and Women's Hospital · USHarvard University · USBoston Children's Hospital · US

Funding

Zoledronic Acid in Treatment of Osteoporosis in PostmenoM01RR002635 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · PI WILLIAMS, GORDON H · 1985 to 2008
$48.4M
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
VLDL and LDL Particle Types as CHD Risk FactorsR01HL070159 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SACKS, FRANK M · 2003 to 2006
$2.8M
Apo A2, C1 and C2 and Diet in human apoB MetabolismR01HL069376 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SACKS, FRANK M · 2002 to 2005
$2.5M
KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISMR01HL056210 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SACKS, FRANK M · 1997 to 2001
$1.2M
POSTMENOPAUSAL ESTROGENS AND ATHEROSCLEROSISR01HL034980 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SACKS, FRANK M · 1986 to 1995
–
NCRR NIH HHS M01 RR002635NCRR NIH HHS RR02635NHLBI NIH HHS R01 HL069376NHLBI NIH HHS R01 HL070159NHLBI NIH HHS R01-HL-34980NHLBI NIH HHS R01-HL-56210NIDDK NIH HHS P30 DK034854
6 · The paper itself

Abstract

objectiveTo characterize human triglyceride-rich lipoproteins (TRL) with and without apoA-II and to study their metabolism in vivo.

methodsPlasma from 11 participants on a controlled diet given a bolus infusion of [D5]l-phenylalanine to label apoB was combined into four pools and applied to anti-apoA-II immunoaffinity columns. Fractions with and without apoA-II were separated into VLDL and IDL by ultracentrifugation; lipids and apolipoproteins were measured. For kinetic measurements, apoB was isolated and hydrolyzed to the constituent amino acids. Tracer enrichment was measured by GCMS. Metabolic rates were determined by SAAM-II.

resultsVLDL and IDL with apoA-II comprised 7% and 9% of total VLDL and IDL apoB respectively. VLDL with apoA-II was enriched in apoC-III, apoE, and cholesterol compared to VLDL without apoA-II. Mean apoB FCR of VLDL with apoA-II was significantly lower than for VLDL without apoA-II (2.80 ± 0.96 pools/day v.s. 5.09 ± 1.69 pools/day, P = 0.009). A higher percentage of VLDL with apoA-II was converted to IDL than was cleared from circulation, compared to VLDL without apoA-II (96 ± 8% vs. 45 ± 22%; P = 0.007). The rate constants for conversion of VLDL to IDL were similar for VLDL with and without apoA-II. Thus, a very low rate constant for clearance accounted for the lower FCR of VLDL with apoA-II.

conclusionVLDL with apoA-II represents a small pool of VLDL particles that has a slow FCR and is predominantly converted to IDL rather than cleared from the circulation.

Indexed as

Apolipoprotein A-IIApolipoprotein B-100Apolipoprotein C-IIIApolipoproteins EBiomarkersFemaleGas Chromatography-Mass SpectrometryHumansKineticsLipoproteins, IDLLipoproteins, VLDLMaleModels, BiologicalTriglyceridesAPOA2 protein, humanAPOB protein, humanApolipoprotein A-IIApolipoprotein B-100Apolipoprotein C-IIIApolipoproteins EBiomarkersLipoproteins, IDLLipoproteins, VLDLTriglyceridesvery low density lipoprotein triglycerideApolipoprotein A-IILipid metabolismTriglyceride rich lipoproteinsVLDL

Identifiers

PMID26071654
PMCPMC4509984
OpenAlexW1954313444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.